Development of a High Performance Bioreactor

高性能生物反应器的开发

• 批准号: 6943873
• 负责人: TODD A MCADAMS
• 金额: $ 31.49万
• 依托单位: RESODYN CORPORATION
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-15 至 2008-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6943873
• 关键词: Fungi; Mammalia; biomedical equipment development; bioreactors; cell proliferation; fermentation; fluidity; gene expression; microorganism culture; microorganism growth; monoclonal antibody; oxygen transport; tissue /cell culture

DESCRIPTION (provided by applicant): The Phase II project specific aim is to perform research to develop and demonstrate an advanced, High Performance Bioreactor (HPBR) fermentation technology that enhances growth characteristics and product expression for various cellular organisms, e.g., bacteria, fungi, yeast, plant, insect and mammalian cells. The HPBR is based upon a novel low-frequency resonant, low-shear mixing technology that has been demonstrated to provide greatly increased oxygen transfer rates and considerably improved mixing compared to conventional technology. The work conducted in Phase I provided compelling evidence that the HPBR is an improved method for the growth and volumetric productivity of a broad range of organisms and pharmaceutical products. The technology has application as both a discovery tool and as an efficient method for production of biopharmaceuticals. The major commercialization opportunity for the HPBR is the culture of hybridoma cells for the production of monoclonal antibodies (MAb). The market for MAb's is projected to grow at a compound rate of 20% over the next 10 years, to $6 billion and serious shortage of production capacity is foreseen. The HPBR technology offers an order of magnitude increase in process intensity compared to conventional stirred bioreactors.

描述（由申请人提供）：II期项目的具体目标是进行研究，以开发和证明一种先进的高性能生物反应器（HPBR）发酵技术，该技术可增强各种细胞生物的生长特性和产物表达，例如，细菌、真菌、酵母、植物、昆虫和哺乳动物细胞。HPBR是基于一种新的低频共振，低剪切混合技术，已被证明提供大大增加的氧气传输速率和显着改善混合相比，传统的技术。在第一阶段进行的工作提供了令人信服的证据，证明HPBR是一种改进的方法，用于广泛的生物体和药物产品的生长和体积生产率。该技术既可以作为发现工具，也可以作为生产生物药物的有效方法。HPBR的主要商业化机会是培养用于生产单克隆抗体（MAb）的杂交瘤细胞。单克隆抗体的市场预计在未来10年内将以20%的复合增长率增长，达到60亿美元，预计生产能力将严重短缺。与传统的搅拌式生物反应器相比，HPBR技术在工艺强度上提高了一个数量级。